A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.

被引：0

作者：

Pandite, L

Burris, HA

Jones, S

Wilding, G

Taylor, C

Versola, MJ

Smith, DA

Stead, A

Koch, KM

Spector, NL

机构：

[1] GlaxoSmithKline, Res Triangle Pk, NC USA

[2] Sarah Cannon Canc Ctr, Nashville, TN USA

[3] Wisconsin Comprehens Canc Ctr, Madison, WI USA

[4] Arizona Canc Ctr, Tucson, AZ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3179

引用

页码：238S / 238S

页数：1

共 50 条

[21] Dose-ranging randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of vorinostat in patients with advanced solid tumors.
Gangadhar, Tara C.
Beumer, Jan Hendrik
Espinoza-Delgado, Igor
Anyang, Bean N.
Karovic, Sanja
Sharma, Manish
Wen, Yujia
Janisch, Linda A.
Kindler, Hedy Lee
Nanda, Rita
Karrison, Theodore
Ratain, Mark J.
Maitland, Michael L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[22] A phase I clinical and pharmacokinetic (PK) study of paclitaxel (P) and docetaxel (D) in patients (PTS) with solid tumors.
Izquierdo, MA
Pontón, JL
García, M
Navarro, M
Mesia, R
Cardenal, F
Gil, M
Germá, JR
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
[23] A phase I dose escalation, safety, and pharmacokinetic (PK) study of BMS-247615 (TAS-103) in patients with refractory solid tumors.
Brahmer, J
Burris, HA
Baker, SD
Elza-Brown, K
Calvert, S
Jones, S
Letrent, S
Cohen, M
Brown, J
DeCillis, A
Carducci, M
Donehower, R
CLINICAL CANCER RESEARCH, 2000, 6 : 4513S - 4513S
[24] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
Iwata, H.
Toi, M.
Fujiwara, Y.
Ito, Y.
Fujii, H.
Nakamura, S.
Aogi, K.
Zaks, T.
Sasaki, Y.
Takashima, S.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
[25] A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors
Mckay, C. E.
Infante, J.
Jones, S.
Bendell, J.
Greco, F. A.
Markus, T. M.
Spigel, D. R.
Yardley, D. A.
Woudenberg, J.
Lathia, C. D.
Burris, H. A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[26] A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
Richardson, Gary Edward
Vaishampayan, Ulka N.
Lin, Lin
Bozon, Viviana
Hui, Ai-Min
Williamson, Stephen K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[27] Phase I and pharmacokinetic (PK) study of a novel cytotoxic agent, PNU-159548, in patients (pts) with solid tumors.
Maja, JAD
Wortelboer, M
van der Gaast, A
Colajori, E
Valota, O
Fiorentini, F
Verweij, J
Sessa, C
CLINICAL CANCER RESEARCH, 1999, 5 : 3729S - 3729S
[28] Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors.
Papadopoulos, Kyriakos P.
Moore, Kathleen N.
Lush, Richard
Desai, Madhuri
Mahmood, Syed
Beckman, Robert A.
Mendell-Harary, Jeanne
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[29] Phase I and pharmacokinetic (PK) study of a new liposome-encapsulated doxorubicin formulation in patients with refractory solid tumors.
Muñoz, C
Muñoz, M
Balaña, C
Pontón, JL
Garcia, M
Llorens, MA
GImeno, M
Rosell, R
Germá, JR
Izquierdo, MA
ANNALS OF ONCOLOGY, 2000, 11 : 134 - 135
[30] Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and-2 Tyrosine Kinases, in Japanese Patients with Solid Tumors
Nakagawa, Kazuhiko
Minami, Hironobu
Kanezaki, Masayuki
Mukaiyama, Akihira
Minamide, Yoshiyuki
Uejima, Hisao
Kurata, Takayasu
Nogami, Toshiji
Kawada, Kenji
Mukai, Hirofumi
Sasaki, Yasutsuna
Fukuoka, Masahiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (02) : 116 - 123

← 1 2 3 4 5 →